Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국

Benzinga

Benzinga Korea 한국
일요일, 9월 06

Crescent Biopharma Inc

CBIONASDAQ
Trade with Public
Trade with Public
$20.88
0.482.35%
가까이에: Sep 4, 5:00 PM EST
$20.88
N/A
시간외: Sep 4, 4:00 PM EST
개요뉴스실적 전망이벤트목표가재무심리지분 현황비교옵션주식 보고서

Crescent Biopharma Analyst Price Targets

Wall Street analyst price targets and consensus rating for Crescent Biopharma (CBIO).

Price Target Range — 4 Quarters

Analyst Consensus — 6 Analysts

5Buy
1Hold
Consensus RatingBuy# Analysts6Avg. Consensus PT$28Upside to Avg. PT+32.2%

Rating Trend — Last 9 Months

Recent Analyst Actions

View all ratings →
DateFirmAnalystActionRating ChangePrice Target
Aug 27, 2026WedbushRobert DriscollMaintainedOutperform$27
Jun 1, 2026HC Wainwright & Co.Mitchell S. KapoorDowngradeBuy→Neutral—
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
Wedbush Reiterates Outperform on Crescent Biopharma, Maintains $27 Price Target

Wedbush analyst Robert Driscoll reiterates Crescent Biopharma (NASDAQ:CBIO) with a Outperform and maintains $27 price target.
Benzinga Newsdesk

This Craig-Hallum Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday

Analysts downgraded ratings on Cardiff Oncology, Crescent Biopharma, Corsair Gaming, Equity Residential and Caesars Entertainment.
Avi Kapoor

PRO
HC Wainwright & Co. Downgrades Crescent Biopharma to Neutral

HC Wainwright & Co. analyst Mitchell S. Kapoor downgrades Crescent Biopharma (NASDAQ:CBIO) from Buy to Neutral.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Maintains Buy on Crescent Biopharma, Lowers Price Target to $22

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Crescent Biopharma (NASDAQ:CBIO) with a Buy and lowers the price target from $25 to $22.
Benzinga Newsdesk

This Crescent Biopharma Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Avi Kapoor

PRO
Guggenheim Initiates Coverage On Crescent Biopharma with Buy Rating, Announces Price Target of $35

Guggenheim analyst Brad Canino initiates coverage on Crescent Biopharma (NASDAQ:CBIO) with a Buy rating and announces Price Target of $35.
Benzinga Newsdesk

데이터 및 API: Benzinga API · 주식 뉴스 API · 애널리스트 등급 API · 회사 로고 API

시장 데이터 제공 Benzinga API

Benzinga

Benzinga Korea 한국

뉴스

파트너 / 기고자

벤징가 글로벌

© 2026 Benzinga | All Rights Reserved